NASDAQ:SNDX
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc's revenue grew 627.8% in fiscal 2025 to $172.4M while operating margin rose to −158.4%. Free cash flow was −$323.2M, −187.5% of revenue, and the diluted share count rose 1.2%.Summary generated from Syndax Pharmaceuticals Inc's SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$172.4M
Revenue growth+627.8%
Revenue, 5-yr CAGR+157.7%
Gross marginn/a
Operating margin−158.4%
Net margin−165.6%
ROICn/a
Return on equity−161.8%
Debt / equityn/a
Free cash flow−$323.2M
FCF margin−187.5%
Share count change+1.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 140 | 0 | 0 | 24 | 172 |
| Operating income | 26 | −152 | −230 | −340 | −273 |
| Net income | 25 | −149 | −209 | −319 | −285 |
| Free cash flow | 29 | −134 | −161 | −275 | −323 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KOther events
Jul 14, 2026 - 4Insider transaction report
Jul 9, 2026 - 4Insider transaction report
Jun 12, 2026 - 8-KEntry into a material agreement
Jun 10, 2026 - 8-KDirector or officer change
Jun 10, 2026 - 8-KEntry into a material agreement
Jun 4, 2026